Genetic testing is useful in the diagnosis of nonhereditary pancreatic conditions: CONCERNS AND OPPORTUNITIES Part 1

Fears about genetic testing

CONCERNS AND OPPORTUNITIES Part 1The decision about whether to proceed with genetic testing is often complex. Currently, the utility of this technique is limited by our incomplete understanding of the etiology of pancreatic disease and our inability to use genetic information to alter the clinical outcomes. Even though these factors will change in the future, the patients’ fears of genetic testing result in significant hesitation.

The author’s group recently studied the motivations and concerns of patients who were offered genetic testing for hereditary pancreatitis. By far, the major concern was insurance discrimination; this is the case even with hemochromatosis, a disease in which genetic testing can identify patients who could be effectively treated with phlebotomy. In a recent study, more than 25% of 124 asymptomatic subjects who were identified as hereditary hemochromatosis carriers reported that they were either required to pay higher premiums or denied coverage altogether. Buy your prescription medications with confidence and without any need for a prescription: buy antibiotics online to see how little you could be paying for the same quality of your treatment.

Unfortunately, as of 2001, fewer than half of the states in the United States (Arizona, California, Colorado, Connecticut, Florida, Georgia, Hawaii, Illinois, Maryland, Minnesota, Nevada, New Hampshire, New Jersey, New York, North Carolina, Ohio, Oregon, Tennessee, Texas, Virginia and Wisconsin) have passed legislation prohibiting genetic discrimination in health insurance. Participation in a research study, rather than attendance at a clinical laboratory, is an attractive option for individuals who do not want their test results to be included in their medical records. In this setting, the results are disclosed directly to the patient, who can then decide to whom the results will be disclosed.

This entry was posted in Pancreatic and tagged Cystic fibrosis transmembrane conductance regulator, Kazal type 1, Pancreatic secretory trypsin inhibitor, Serine protease inhibitor, Trypsin, Trypsinogen.